BioVie Inc. announced on April 16, 2025, the initiation of its Phase 2 SUNRISE-PD clinical trial and the enrollment of the first patient. This trial is evaluating bezisterim, the company's anti-inflammatory and insulin-sensitizing candidate, in patients with early Parkinson's disease who have not yet received carbidopa/levodopa treatment.
The SUNRISE-PD trial incorporates a hybrid, decentralized design, offering patients the option for remote participation. This approach aims to enhance accessibility and broaden participation in Parkinson's disease research.
Patient recruitment for the study is being supported by prominent organizations including The Michael J. Fox Foundation, the Davis Phinney Foundation, and The Parkinson’s Foundation. This trial represents a crucial step in advancing bezisterim as a potential disease-modifying therapy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.